Immunotherapy in myasthenia gravis in the era of biologics
Immunotherapy in myasthenia gravis in the era of biologics
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis (MG). Most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Severe cases and acute worsening require intravenous immunoglobulin or plasmapheresis before oral immunosuppressants start having a...
Alternative Titles
Full title
Immunotherapy in myasthenia gravis in the era of biologics
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2159983886
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2159983886
Other Identifiers
ISSN
1759-4758,1759-4766
E-ISSN
1759-4766
DOI
10.1038/s41582-018-0110-z
